Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their potential benefit in supporting or treating depression. Multiple meta-analyses and systematic reviews of randomized controlled trials indicate that omega-3 supplementation, especially products with higher EPA content, may have a modest but statistically significant effect in reducing depressive symptoms, particularly in individuals with major depressive disorder (MDD) and those who do not respond fully to standard antidepressant treatments. The proposed mechanisms include modulation of neurotransmitter pathways (such as serotonin and dopamine), anti-inflammatory actions, and effects on neuronal membrane fluidity. However, the evidence is mixed. Some large, well-controlled studies have failed to show significant benefits, and the effect size across studies is generally small. The benefits appear more pronounced in people with clinical depression than in those with mild symptoms or in the general population. Current clinical guidelines, such as those from the American Psychiatric Association, acknowledge the possible benefit of omega-3s as an adjunctive treatment but do not recommend them as monotherapy. Overall, omega-3 fatty acids are considered a relatively low-risk intervention, but more research is needed to clarify optimal dosing, formulations, and patient populations most likely to benefit.

More about omega-3 fatty acids
More about Depression

Other ingredients used for Depression

Other health conditions supported by omega-3 fatty acids

Products containing omega-3 fatty acids

Nature's Sunshine Flax Seed Oil (With Lignans)